Current Rating and Its Significance
MarketsMOJO’s 'Buy' rating for Suraksha Diagnostic Ltd indicates a positive outlook on the stock’s potential for investors seeking growth within the healthcare services sector. This recommendation is based on a comprehensive evaluation of the company’s quality, valuation, financial trends, and technical indicators. The rating suggests that the stock is expected to outperform the broader market or its peers over the medium term, making it a favourable choice for investors looking to capitalise on the company’s strengths.
Quality Assessment
As of 13 September 2026, Suraksha Diagnostic Ltd holds a 'good' quality grade. This reflects the company’s robust operational performance and sound financial health. Notably, the company demonstrates a strong ability to service its debt, with a Debt to EBITDA ratio of just 1.40 times, signalling manageable leverage and prudent financial management. Furthermore, the company’s operating profit has exhibited impressive growth, expanding at an annual rate of 60.46%, underscoring its capacity to generate increasing earnings from core operations.
The recent quarterly results reinforce this quality narrative. In June 2026, Suraksha Diagnostic reported a profit after tax (PAT) of ₹13.01 crores, marking a 61.7% increase compared to the average of the previous four quarters. Net sales reached a record ₹87.65 crores, while profit before depreciation, interest, and taxes (PBDIT) hit a high of ₹30.44 crores. These figures highlight the company’s operational resilience and ability to rebound after two consecutive quarters of negative results.
Valuation Perspective
The valuation grade for Suraksha Diagnostic Ltd is currently assessed as 'fair'. The company’s return on capital employed (ROCE) stands at 15.5%, which is a respectable figure indicating efficient use of capital to generate profits. Its enterprise value to capital employed ratio is 5.1, suggesting that the stock is trading at a discount relative to its peers’ historical valuations. This discount could present an attractive entry point for investors seeking value within the healthcare services sector.
Despite a modest price-to-earnings-to-growth (PEG) ratio of 25.5, the stock has delivered a 3.99% return over the past year, while profits have increased by 2%. This combination of steady profit growth and reasonable valuation metrics supports the 'Buy' rating, signalling that the stock is not excessively priced given its growth prospects.
Financial Trend Analysis
The financial trend for Suraksha Diagnostic Ltd is rated as 'positive'. The company’s recent quarterly performance, with record sales and profits, indicates a strong upward trajectory. The turnaround from previous quarters of negative results to positive earnings growth demonstrates effective management strategies and operational improvements.
Year-to-date, the stock has appreciated by 21.10%, with a six-month gain of 25.19% and a one-month surge of 25.87%. These returns reflect growing investor confidence and momentum in the stock, supported by solid fundamentals and improving financial health.
Technical Outlook
From a technical standpoint, Suraksha Diagnostic Ltd is rated as 'bullish'. The stock’s recent price movements show positive momentum despite a minor one-day decline of 0.93% and a one-week dip of 2.14%. The overall trend remains upward, supported by strong institutional holdings of 36.7%, which often provide stability and informed backing to the stock’s price action.
Institutional investors typically possess greater resources and analytical capabilities, which can contribute to more informed decision-making and potentially reduce volatility. Their significant stake in Suraksha Diagnostic Ltd is a positive signal for retail investors considering the stock.
Our latest weekly pick is live! This Large Cap from Diamond & Gold Jewellery comes with clear entry and exit targets. See the detailed report with target price now!
- - Clear entry/exit targets
- - Target price revealed
- - Detailed report available
Implications for Investors
For investors, the 'Buy' rating on Suraksha Diagnostic Ltd suggests that the stock is well-positioned to deliver favourable returns relative to its sector and the broader market. The combination of strong quality metrics, fair valuation, positive financial trends, and bullish technical signals provides a comprehensive foundation for confidence in the stock’s prospects.
Investors should consider the company’s microcap status, which can entail higher volatility and risk compared to larger companies. However, the demonstrated growth in operating profit and recent positive quarterly results indicate that Suraksha Diagnostic Ltd is navigating its market environment effectively.
Moreover, the stock’s discount to peer valuations and solid institutional backing may offer a margin of safety and potential for capital appreciation. As always, investors are advised to assess their risk tolerance and investment horizon when considering exposure to microcap healthcare stocks.
Summary
In summary, Suraksha Diagnostic Ltd’s current 'Buy' rating by MarketsMOJO, last updated on 01 September 2026, is supported by a strong quality profile, reasonable valuation, positive financial momentum, and encouraging technical indicators as of 13 September 2026. This rating reflects the company’s ability to generate growth and value for shareholders in the evolving healthcare services sector.
Investors looking for exposure to a healthcare services company with improving fundamentals and a favourable market outlook may find Suraksha Diagnostic Ltd an attractive addition to their portfolio.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
